Leállítva2. fázis
Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer
A legfontosabb adatok
- Ki végzi
- University Health Network, Toronto
- Hol
- Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 5 fő vett részt
- Kezdés
- 2022. jan. 24.
- Befejezés
- 2025. febr. 19.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- cfDNA blood test
- Nivolumab
- Ipilimumab
- Platinum-based Chemotherapy
- A regiszteradat frissítve
- 2026. január 8.
- Miért állt le
- Low accrual
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years at the time of screening or age of consent
- Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Weight ≥ 35 kg
- Must have a life expectancy of at least 12 weeks
- Recurrent or newly diagnosed metastatic non-small cell lung cancer
- Tumor PDL1 status <50%
- Non-Squamous and squamous histologies are eligible
- Histologies with targetable mutations (EGFR, ALK, ROS1) are not eligible, regardless of prior treatment with tyrosine kinase inhibitors
- No prior radiation, surgery or chemotherapy is allowed for the current diagnosis of non-small cell lung cancer
- Adequate organ and marrow function
Ki nem vehet részt
- Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment
- Prior receipt of any immune-mediated therapy
- Incomplete surgical resection
- Concurrent enrolment in another therapeutic clinical study. Enrolment in observational studies will be allowed
- Any toxicity (excluding alopecia) from prior standard therapy that has not been completely resolved to baseline at the time of consent
- Participants with prior history of myocardial infarction, transient ischemic attack, congestive heart failure ≥ Class 3 based on New York Heart Association Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment
- Active or prior documented autoimmune disorders within the past 3 years prior to the scheduled first dose of study treatment with exceptions
- Known allergy or hypersensitivity to investigational product formulations
- Current or prior use of immunosuppressive medication within 14 days prior to the scheduled first dose of study treatment with exceptions
- Receipt of live, attenuated vaccine within 30 days prior to the scheduled first dose of study treatment - Major surgery within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery
- Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of subject safety or study results
- Participants with confirmed human immunodeficiency virus (even if viral load is undetectable), chronic or active hepatitis B or C, or active hepatitis A
- History of primary immunodeficiency, solid organ transplantation, or active tuberculosis (by clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice)
- Other invasive malignancy within 2 years. Non-invasive malignancies (i.e., cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition
- History of more than one event of infusion related reactions requiring permanent discontinuation of intravenous drug treatment
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring antibiotic therapy, uncontrolled hypertension, bleeding diatheses, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring adverse events, or compromise the ability of the subject to give written informed consent
- Females who are pregnant, lactating, or intend to become pregnant during their participation in the study
- Participants who are involuntarily incarcerated or are unable to willingly provide consent or are unable to comply with the protocol procedures
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer that has metastasized (has spread to other parts of the body) and to see what effects these drugs have on these tumors.
A vizsgálat csoportja
- Non-Small cell Lung CancerA vizsgált kezelés
Nivolumab, intravenously (given by vein), once every 3 weeks Ipilimumab, intravenously (given by vein), once every 6 weeks Participants will have blood samples taken for cell free deoxyribonucleic acid (cfDNA) testing. If there is an increasing or stable tumor cfDNA, platinum-doublet chemotherapy will be given.
Kezelés: cfDNA blood test, Nivolumab, Ipilimumab és Platinum-based Chemotherapy
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Beyond Chemotherapy: Nivolumab-Ipilimumab With cfDNA-guided Treatment Intensification as a Chemotherapy-sparing Strategy in Metastatic Non-small Cell Lung Cancer
- A regiszteradat frissítve
- 2026. január 8.